RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
RT @EricTopol: Another day, another report on hydoxychloroquine absence of efficacy. New @NEJM trial published today https://t.co/k2oCZhtw0…
Coalizão I no NEJM! Parabéns, colegas! https://t.co/HsvOukjikt
RT @DrChoueiri: Just NOW in @NEJM —another RCT of #HCQ this time from Brazil showing no benefit in #COVID19 (with minimal O2 req) https://t…
RT @DrChoueiri: Just NOW in @NEJM —another RCT of #HCQ this time from Brazil showing no benefit in #COVID19 (with minimal O2 req) https://t…
RT @BogochIsaac: No benefit of hydroxychloroquine in a well-designed study: "Among patients hospitalized with mild-to-moderate #COVID19, t…
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
No benefit of hydroxychloroquine in a well-designed study: "Among patients hospitalized with mild-to-moderate #COVID19, the use of hydroxychloroquine, alone or with azithromycin, did not improve clinical status at 15 days as compared with standard care."
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 | NEJM https://t.co/yuRWb3faeN #COVID19
RT @leticiakawano: 1/ Our study (Coalition I) on HCQ and azithromycin for #Covid19 is out! This study is the effort of an unprecedented co…
Snif, ça marche toujours pas, même au sacro-saint Brésil.. Plus d'info ici : https://t.co/lqLQcC0unR
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 | NEJM This doesn't go! @jsmadero @germanfajardo @carlos_sierra @NefrologiaINC @GeriatriaINNSZ https://t.co/21LM7AXCeV
RT @PauloLotufo: Brasil chuta a cloroquina. Parabéns, aos meus seguidores @f_g_zampieri @leticiakawano pela publicação e pelo sigilo mantid…
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
RT @EricTopol: Another day, another report on hydoxychloroquine absence of efficacy. New @NEJM trial published today https://t.co/k2oCZhtw0…
RT @otavio_ranzani: Estudo randomizado brasileiro no @NEJM testando Hidroxicloroquina e Azitromicina. Parabéns a todas e todos! O result…
RT @leticiakawano: 1/ Our study (Coalition I) on HCQ and azithromycin for #Covid19 is out! This study is the effort of an unprecedented co…
RT @EricTopol: Another day, another report on hydoxychloroquine absence of efficacy. New @NEJM trial published today https://t.co/k2oCZhtw0…
RT @DrChoueiri: Just NOW in @NEJM —another RCT of #HCQ this time from Brazil showing no benefit in #COVID19 (with minimal O2 req) https://t…
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
RT @otavio_ranzani: Estudo randomizado brasileiro no @NEJM testando Hidroxicloroquina e Azitromicina. Parabéns a todas e todos! O result…
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
RT @otavio_ranzani: Estudo randomizado brasileiro no @NEJM testando Hidroxicloroquina e Azitromicina. Parabéns a todas e todos! O result…
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
Just NOW in @NEJM —another RCT of #HCQ this time from Brazil showing no benefit in #COVID19 (with minimal O2 req) https://t.co/EiFH90RYFl @COVID19nCCC @OncoAlert @chadinabhan @mtmdphd @tmprowell @Rfonsi1 @FabioSchutz78 @hemoncwarner
RT @EricTopol: Another day, another report on hydoxychloroquine absence of efficacy. New @NEJM trial published today https://t.co/k2oCZhtw0…
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 | NEJM https://t.co/AIniiNyFg9
1/ Our study (Coalition I) on HCQ and azithromycin for #Covid19 is out! This study is the effort of an unprecedented collaboration (Coalition Covid19 Brasil) established between major Brazilian hospitals and research networks/Institutes. https://t.co/f5
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
Nouvelle étude venant du Brésil : https://t.co/d9y2vnyS09 CONCLUSIONS : Among patients hospitalized with mild-to-moderate Covid-19, the use of hydroxychloroquine, alone or with azithromycin, did not improve clinical status at 15 days as compared with stan
RT @EricTopol: Another day, another report on hydoxychloroquine absence of efficacy. New @NEJM trial published today https://t.co/k2oCZhtw0…
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
RT @deniswirtz: I have never seen so many negative results published in so many prestigious journals. https://t.co/v2CunAcerA
RT @PauloLotufo: Brasil chuta a cloroquina. Parabéns, aos meus seguidores @f_g_zampieri @leticiakawano pela publicação e pelo sigilo mantid…
RT @otavio_ranzani: Estudo randomizado brasileiro no @NEJM testando Hidroxicloroquina e Azitromicina. Parabéns a todas e todos! O result…
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 | NEJM https://t.co/2YrZPSYZk2
Sérieusement, ça commence à être ennuyeux toutes ces études sur l’hydroxychloroquine !!! Je crois qu’on a compris, ça ne marche pas !! Pas du tout !! https://t.co/Wz9wOIzVqT
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
RT @otavio_ranzani: Estudo randomizado brasileiro no @NEJM testando Hidroxicloroquina e Azitromicina. Parabéns a todas e todos! O result…
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
Brasil chuta a cloroquina. Parabéns, aos meus seguidores @f_g_zampieri @leticiakawano pela publicação e pelo sigilo mantido (pouco usual nos dias de hoje). https://t.co/BmXlbyadkB
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
RT @otavio_ranzani: Estudo randomizado brasileiro no @NEJM testando Hidroxicloroquina e Azitromicina. Parabéns a todas e todos! O result…
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
etc
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
RT @otavio_ranzani: Estudo randomizado brasileiro no @NEJM testando Hidroxicloroquina e Azitromicina. Parabéns a todas e todos! O result…
Cough cough.
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 | NEJM https://t.co/nWOXxd2H0s
RT @otavio_ranzani: Estudo randomizado brasileiro no @NEJM testando Hidroxicloroquina e Azitromicina. Parabéns a todas e todos! O result…
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
Estudo randomizado brasileiro no @NEJM testando Hidroxicloroquina e Azitromicina. Parabéns a todas e todos! O resultado: sem efeito algum e mais eventos adversos em doentes hospitalizados. https://t.co/NcmYIDBnjt https://t.co/RSfDdv9GeU
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
RT @DrDenaGrayson: 🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate…
RT @EricTopol: Another day, another report on hydoxychloroquine absence of efficacy. New @NEJM trial published today https://t.co/k2oCZhtw0…
🚨BREAKING: Randomized study shows that #hydroxychloroquine ± azithromycin has NO BENEFIT in patients with mild/moderate #COVID19. But arrhythmias and elevated liver enzymes levels were MORE FREQUENT in patients receiving #hydroxychloroquine vs. control.
RT @EricTopol: Another day, another report on hydoxychloroquine absence of efficacy. New @NEJM trial published today https://t.co/k2oCZhtw0…
RT @EricTopol: Another day, another report on hydoxychloroquine absence of efficacy. New @NEJM trial published today https://t.co/k2oCZhtw0…
RT @deniswirtz: I have never seen so many negative results published in so many prestigious journals. https://t.co/v2CunAcerA
Terminemos con la #hidroxicloroquina con o sin #azitromicina. Ni los estudios en #Brasil con pacientes leves y moderados la respaldan. https://t.co/KdO13PoyCS
Sai o Coalizão I, Estudo Brasileiro sobre o uso de HCQ nas formas leves e moderadas de Covid19. Novamente - Sem benefício algum. https://t.co/6eKuLWDmkJ
RT @EricTopol: Another day, another report on hydoxychloroquine absence of efficacy. New @NEJM trial published today https://t.co/k2oCZhtw0…
RT @EricTopol: Another day, another report on hydoxychloroquine absence of efficacy. New @NEJM trial published today https://t.co/k2oCZhtw0…
RT @deniswirtz: I have never seen so many negative results published in so many prestigious journals.
RT @EricTopol: Another day, another report on hydoxychloroquine absence of efficacy. New @NEJM trial published today https://t.co/k2oCZhtw0…
RT @EricTopol: Another day, another report on hydoxychloroquine absence of efficacy. New @NEJM trial published today https://t.co/k2oCZhtw0…
RT @EricTopol: Another day, another report on hydoxychloroquine absence of efficacy. New @NEJM trial published today https://t.co/k2oCZhtw0…
@Minsa_Peru @INS_Peru tomen nota. Hidroxicloroquina no funciona!
@MSNBC @ChrisCuomo @ABC Among patients hospitalized with mild-to-moderate Covid-19, the use of hydroxychloroquine, alone or with azithromycin, did not improve clinical status at 15 days as compared with standard care. https://t.co/g4s0A2q1XA
RT @EricTopol: Another day, another report on hydoxychloroquine absence of efficacy. New @NEJM trial published today https://t.co/k2oCZhtw0…
Hace unos meses muchos decían que era inmoral no utilizar masivamente la hidroxicloroquina a partir de algunos reportes observacionales. Hoy, los sucesivos estudios de calidad que están refutando su supuesta utilidad. https://t.co/h0FSMbq590
RT @deniswirtz: I have never seen so many negative results published in so many prestigious journals.
RT @EricTopol: Another day, another report on hydoxychloroquine absence of efficacy. New @NEJM trial published today https://t.co/k2oCZhtw0…